Activity of BCMA-targeting agents following prior anti-BCMA exposure*
| Agent . | Population/design . | n . | % ORR (≥CR); median DOR in months (95% CI); median PFS in months (95% CI) at reported median follow-up (if available) . | |||||
|---|---|---|---|---|---|---|---|---|
| Prior BCMA CART . | Prior BCMA BsAb . | Prior BCMA ADC . | Prior BCMA CART . | Prior BCMA BsAb . | Prior BCMA ADC . | Any prior anti-BCMA . | ||
| Belamaf13,18,19 | Commercial belamaf after prior anti-BCMA CART; 3 retrospective single-in stitution analysis—pooled results | 22 | None | None | 18% (NR); NR; NR | — | — | — |
| Ide-cel5 | KarMMa-1; prospective phase 2 trial. Analysis of patients retreated with ide-cel upon progression. | 28 | — | — | 21% (0% ≥ CR); NR; 1.0 (1.0-2.1) | — | — | — |
| Ide-cel 12† | Commercial ide-cel recipients; retrospective multi-institution analysis | 5 | 7 | 36 | 100% (60% ≥ CR) NR; NE | 85.7% (42.9% ≥ CR); NR; 2.83 | 67.6% (21.6% ≥ CR); NR; 3.19 | 74% (29% ≥ CR); NR; 3.2 |
| Cilta-cel14 | Cilta-cel recipients (cohort C CARTITUDE-2); prospective phase 2 trial | None | 7 | 13 | — | 57.1% (14.3% ≥ CR); 8.2 (4.4-NE); 5.3 (0.6-NE) at 10.9 months | 61.5% (38.5% ≥ CR); 11.5 (7.9-NE); 9.5 (0.99-NE) at 11.8 months | 60% (30% ≥ CR) 11.5 (7.9-NE); 9.1 (1.5-NE) at 11.3 months |
| CT103A11 | Recipients of CT103A BCMA CART (n = 103 total); subgroup analysis, prospective phase 1 trial | 12 | None | None | 75% (41.7% ≥ CR); 6.3 (2.9-NE); NR at 12.2 months | — | — | — |
| Teclistamab15† | Teclistamab recipients (MajesTec-1 cohort C), prospective phase 1/2 trial | 15 | None | 29 | 53.3% (26.7% ≥ CR); NR; NR at 12.5 months | — | 55.2% (24.1% ≥ CR); NR; NR at 12.5 months | 52.5% (27.5% ≥ CR); NE (10.5-NE); NR at 12.5 months |
| Elranatamab16† | Elranatamab recipients (4 MagnetisMM prospective studies); pooled sub-group analysis | 36 | None | 59 | 52.8% (19.6% ≥ CR); NE (9.8-NE); 10.0 (1.9-NE) at 11.3 months | — | 42.4% (18.7% ≥ CR); 13.9 (6.8-NE); 3.9 (1.9-6.6) at 11.3 months | 46% (18.4% ≥ CR); 17.1 (9.8-NE); 5.5 (2.2-10.0) at 11.3 months |
| Agent . | Population/design . | n . | % ORR (≥CR); median DOR in months (95% CI); median PFS in months (95% CI) at reported median follow-up (if available) . | |||||
|---|---|---|---|---|---|---|---|---|
| Prior BCMA CART . | Prior BCMA BsAb . | Prior BCMA ADC . | Prior BCMA CART . | Prior BCMA BsAb . | Prior BCMA ADC . | Any prior anti-BCMA . | ||
| Belamaf13,18,19 | Commercial belamaf after prior anti-BCMA CART; 3 retrospective single-in stitution analysis—pooled results | 22 | None | None | 18% (NR); NR; NR | — | — | — |
| Ide-cel5 | KarMMa-1; prospective phase 2 trial. Analysis of patients retreated with ide-cel upon progression. | 28 | — | — | 21% (0% ≥ CR); NR; 1.0 (1.0-2.1) | — | — | — |
| Ide-cel 12† | Commercial ide-cel recipients; retrospective multi-institution analysis | 5 | 7 | 36 | 100% (60% ≥ CR) NR; NE | 85.7% (42.9% ≥ CR); NR; 2.83 | 67.6% (21.6% ≥ CR); NR; 3.19 | 74% (29% ≥ CR); NR; 3.2 |
| Cilta-cel14 | Cilta-cel recipients (cohort C CARTITUDE-2); prospective phase 2 trial | None | 7 | 13 | — | 57.1% (14.3% ≥ CR); 8.2 (4.4-NE); 5.3 (0.6-NE) at 10.9 months | 61.5% (38.5% ≥ CR); 11.5 (7.9-NE); 9.5 (0.99-NE) at 11.8 months | 60% (30% ≥ CR) 11.5 (7.9-NE); 9.1 (1.5-NE) at 11.3 months |
| CT103A11 | Recipients of CT103A BCMA CART (n = 103 total); subgroup analysis, prospective phase 1 trial | 12 | None | None | 75% (41.7% ≥ CR); 6.3 (2.9-NE); NR at 12.2 months | — | — | — |
| Teclistamab15† | Teclistamab recipients (MajesTec-1 cohort C), prospective phase 1/2 trial | 15 | None | 29 | 53.3% (26.7% ≥ CR); NR; NR at 12.5 months | — | 55.2% (24.1% ≥ CR); NR; NR at 12.5 months | 52.5% (27.5% ≥ CR); NE (10.5-NE); NR at 12.5 months |
| Elranatamab16† | Elranatamab recipients (4 MagnetisMM prospective studies); pooled sub-group analysis | 36 | None | 59 | 52.8% (19.6% ≥ CR); NE (9.8-NE); 10.0 (1.9-NE) at 11.3 months | — | 42.4% (18.7% ≥ CR); 13.9 (6.8-NE); 3.9 (1.9-6.6) at 11.3 months | 46% (18.4% ≥ CR); 17.1 (9.8-NE); 5.5 (2.2-10.0) at 11.3 months |